Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT A DICHMANN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1245232578
CMS profile
328270
Location
SANTA MARIA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$26.48

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $26.48 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Astellas Pharma US Inc $26.48 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT A DICHMANN

NPI 1245232578 · CMS profile ID 328270

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SANTA MARIA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245232578?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT A DICHMANN, NPI 1245232578, CMS profile ID 328270. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245232578?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ROBERT A DICHMANN, NPI 1245232578, CMS profile ID 328270. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245232578?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ROBERT A DICHMANN, NPI 1245232578, CMS profile ID 328270, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1245232578?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $26.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $26.4806/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034160385 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $328.73 22
PY2020 $104.19 8
PY2021 $18.12 2
PY2022 $14.08 1
PY2023 $26.48 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,981.45 2
PY2024 Principal investigator $7,185.45 2
PY2023 Principal investigator $33,549.76 11
PY2022 Principal investigator $162,021.03 21
PY2021 Principal investigator $97,528.06 21
PY2020 Principal investigator $227,117.30 35
PY2019 Principal investigator $393,411.87 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $661.72 12/31/2019 Non-covered Recipient Entity
Translational Research In Oncology-
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care No dispute reported 06/30/2026 684993973
Principal investigator 1 AstraZeneca UK Limited $262.33 12/31/2019 Non-covered Recipient Entity
Translational Research In Oncology-
This is a randomized open label multi center global Phase III study to determine the efficacy and safety of MEDI4736 as monotherapy and MEDI4736 tremelimumab combination therapy versus SoC therapy in the target patient population No dispute reported 06/30/2026 685001703
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,650.00 12/27/2019 Non-covered Recipient Entity
Translational Research In Oncology-
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care No dispute reported 06/30/2026 684993897
Principal investigator 1 Hoffmann-La Roche Limited $8,511.80 12/13/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
ABT 199 GDC 0199 IN 1L DLBCL No dispute reported 06/30/2026 681065823
Principal investigator 1 PFIZER INC. $100.00 11/14/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671657189
Principal investigator 1 Seattle Genetics, Inc. $400.00 10/18/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 709079149
Principal investigator 1 Seattle Genetics, Inc. $1,098.00 10/09/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 709079145
Principal investigator 1 Seattle Genetics, Inc. $4,224.00 10/09/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 709079147
Principal investigator 1 Hoffmann-La Roche Limited $8,535.00 09/12/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
ABT 199 GDC 0199 IN 1L DLBCL No dispute reported 06/30/2026 681064761
Principal investigator 1 PFIZER INC. $50.00 07/30/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671657187
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,866.50 07/26/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE No dispute reported 06/30/2026 640712837
Principal investigator 1 Seattle Genetics, Inc. $3,901.00 07/22/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678824779
Principal investigator 1 Seattle Genetics, Inc. $6.00 07/02/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678824775
Principal investigator 1 Seattle Genetics, Inc. $21.00 07/02/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678824777
Principal investigator 1 Amgen Inc. $158.00 06/22/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
P3 Adjuvant Breast Cancer No dispute reported 06/30/2026 675794567
Principal investigator 1 AstraZeneca UK Limited $3,310.00 06/03/2019 Non-covered Recipient Entity
Translational Research In Oncology-
This is a randomized open label multi center global Phase III study to determine the efficacy and safety of MEDI4736 as monotherapy and MEDI4736 tremelimumab combination therapy versus SoC therapy in the target patient population No dispute reported 06/30/2026 685001695
Principal investigator 1 Seattle Genetics, Inc. $219.00 05/22/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678824767
Principal investigator 1 Seattle Genetics, Inc. $842.00 05/22/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678824769
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,639.00 05/16/2019 Non-covered Recipient Entity
Translational Oncology Research International
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices No dispute reported 06/30/2026 639763645
Principal investigator 1 Eli Lilly and Company $2,509.00 05/14/2019 Non-covered Recipient Entity
TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL INC
A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF FIRST-LINE METASTATIC PANCREATIC CANCER No dispute reported 06/30/2026 654298481
Principal investigator 1 PFIZER INC. $50.00 05/02/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671626043
Principal investigator 1 Seattle Genetics, Inc. $10,610.00 05/01/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678824765
Principal investigator 1 Incyte Corporation $1,280.00 04/29/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES No dispute reported 06/30/2026 666475315
Principal investigator 1 Incyte Corporation $2,000.00 04/23/2019 Non-covered Recipient Entity
SANSUM CLINIC SANTA BARBARA
A Phase 2, Open Label, 2 Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor, CITADEL 204 No dispute reported 06/30/2026 666498911
Principal investigator 1 Seattle Genetics, Inc. $9,435.00 04/18/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678824773
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,575.00 04/09/2019 Non-covered Recipient Entity
Translational Oncology Research International
Phase IIB 1L NSCLC Flat Dose Nivo Combo Schedule Safety No dispute reported 06/30/2026 639763653
Principal investigator 1 Eli Lilly and Company $242.10 04/08/2019 Non-covered Recipient Entity
TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL INC
A PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF FIRST-LINE METASTATIC PANCREATIC CANCER No dispute reported 06/30/2026 654296479
Principal investigator 1 EMD Serono, Inc. $285.00 03/26/2019 Non-covered Recipient Entity
UCLA TRIO US CAN CARE ASSOC MED GRP INC
EMR 100070-007 No dispute reported 06/30/2026 703032315
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,973.00 03/22/2019 Non-covered Recipient Entity
Translational Oncology Research International
A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen No dispute reported 06/30/2026 639763635
Principal investigator 1 Amgen Inc. $2,624.00 03/20/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY GROUP
P3 Adjuvant Breast Cancer No dispute reported 06/30/2026 675784057
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $500.00 03/19/2019 Non-covered Recipient Entity
Translational Oncology Research International
A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving One Prior Systemic Regimen No dispute reported 06/30/2026 639763639
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,795.68 03/14/2019 Non-covered Recipient Entity
Translational Research In Oncology-
A Phase III Randomized Open Label Multi Center Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small Cell Lung Cancer NSCLC MYSTIC No dispute reported 06/30/2026 684993893
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,485.00 03/07/2019 Non-covered Recipient Entity
Translational Oncology Research International
A Dose Frequency Optimization, Phase IIIBIV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mgkg or 240 mg Every No dispute reported 06/30/2026 639763641
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $58,060.30 03/06/2019 Non-covered Recipient Entity
Translational Oncology Research International
Phase III 1L Metastatic RCC Nivo Ipi Cabo No dispute reported 06/30/2026 708963897
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $500.00 03/05/2019 Non-covered Recipient Entity
Translational Oncology Research International
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 639763637
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $42,014.50 03/05/2019 Non-covered Recipient Entity
Translational Oncology Research International
Phase IIIBIV Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previous Untreated, Advanced or Metastatic RCC No dispute reported 06/30/2026 639763647
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $929.67 02/25/2019 Non-covered Recipient Entity
Central Coast Medical Oncology Corporation
Phase IIB 1L NSCLC Flat Dose Nivo Combo Schedule Safety No dispute reported 06/30/2026 639763651
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,355.40 02/19/2019 Non-covered Recipient Entity
Translational Oncology Research International
Phase III Multiple Myeloma 3L Combo nivo - elo No dispute reported 06/30/2026 639763657
Principal investigator 1 Incyte Corporation $2,000.00 02/12/2019 Non-covered Recipient Entity
SANSUM CLINIC SANTA BARBARA
A Phase 2, Open Label, 2 Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor, CITADEL 204 No dispute reported 06/30/2026 666498937
Principal investigator 1 Incyte Corporation $1,500.00 02/12/2019 Non-covered Recipient Entity
SANSUM CLINIC SANTA BARBARA
A Phase 2, Open Label, 2 Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor, CITADEL 204 No dispute reported 06/30/2026 666498939
Principal investigator 1 Incyte Corporation $6,000.00 02/12/2019 Non-covered Recipient Entity
SANSUM CLINIC SANTA BARBARA
A Phase 2, Open Label, 2 Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor, CITADEL 204 No dispute reported 06/30/2026 666498941
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,962.00 02/11/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY INC
MONALEESA 3 A RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED STUDY OF RIBOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO HAVE RECEIVED NO OR ONLY ONE LINE No dispute reported 06/30/2026 640727611
Principal investigator 1 Novartis Pharmaceuticals Corporation $94,395.74 02/08/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE No dispute reported 06/30/2026 753935086
Principal investigator 1 Incyte Corporation $18.00 02/05/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES No dispute reported 06/30/2026 666475303
Principal investigator 1 Hoffmann-La Roche Limited $7,585.00 02/04/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
ABT 199 GDC 0199 IN 1L DLBCL No dispute reported 06/30/2026 681059361
Principal investigator 1 PFIZER INC. $100.00 01/31/2019 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 671618683
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,545.00 01/30/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
TRINITI1 A PHASE I AND OR II SINGLE ARM OPEN LABEL STUDY OF RIBOCICLIB IN COMBINATION WITH EVEROLIMUS PLUS EXEMESTANE IN THE TREATMENT OF MEN AND POSTMENOPAUSAL WOMEN WITH HR PLUS HER2 LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON No dispute reported 06/30/2026 640712841
Principal investigator 1 Seattle Genetics, Inc. $3,901.00 01/29/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 678824771
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $45.91 01/28/2019 Non-covered Recipient Entity
Central Coast Medical Oncology Corporation
Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway No dispute reported 06/30/2026 639763649
Principal investigator 1 Eli Lilly and Company $282.20 01/28/2019 Non-covered Recipient Entity
TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL INC
RANDOMIZED STUDY OF AM0010 IN COMBINATION WITH FOLFOX COMPARED TO FOLFOX ALONE AS SECOND-LINE TX IN PTS WITH META PANCREATIC CANCER THAT HAS PROGRESSED DURING OR FOLLOWING A FIRST-LINE GEMCITABINE CONTAINING REGIMEN No dispute reported 06/30/2026 654298943
Principal investigator 1 EMD Serono, Inc. $36.00 01/18/2019 Non-covered Recipient Entity
UCLA TRIO US CAN CARE ASSOC MED GRP INC
EMR 100070-007 No dispute reported 06/30/2026 703030013
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $33,940.50 01/16/2019 Non-covered Recipient Entity
Translational Oncology Research International
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies CheckMate 627 No dispute reported 06/30/2026 639763643
Principal investigator 1 Novartis Pharmaceuticals Corporation $421.52 01/01/2019 Non-covered Recipient Entity
CENTRAL COAST MEDICAL ONCOLOGY
TWO ARM RANDOMIZED PHASE 3 STUDY IN HIGH RISK NSCLC COMPARING CANAKINUMAB VS PLACEBO IN ADJUVANT SETTING No dispute reported 06/30/2026 640712833